Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
Journal of Cancer Prevention
;
: 74-81, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-173854
ABSTRACT
Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and clinic management. The technical monitoring of BCR-ABL1 with quantitative real time-PCR has been used in assessing patient outcome. The cytogenetic mark of CML is Philadelphia chromosome, that is formed by reciprocal chromosomal translocations between human chromosome 9 and 22, t(922) (q³⁴q¹¹). It makes a BCR-ABL1 fusion protein with an anomaly tyrosine kinase activity that promotes the characteristic proliferation of progenitor cells in CML and acute lymphoblastic lymphoma. The targeting of BCR-ABL1 fusion kinase is the first novel paradigm of molecularly targeted curing.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fosfotransferasas
/
Células Madre
/
Translocación Genética
/
Proteínas Tirosina Quinasas
/
Cromosoma Filadelfia
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Cromosomas Humanos
/
Citogenética
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Métodos
Límite:
Humanos
Idioma:
Inglés
Revista:
Journal of Cancer Prevention
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS